Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Le... von Robak, Tadeusz, Dmoszynska, Anna, Solal-Céligny, Philippe, Warzocha, Krzysztof, Loscertales, Javier, Catalano, John, Afanasiev, Boris V, Larratt, Loree, Geisler, Christian H, Montillo, Marco, Zyuzgin, Ilya, Ganly, Peter S, Dartigeas, Caroline, Rosta, András, Maurer, Jörg, Mendila, Myriam, Saville, M Wayne, Valente, Nancy, Wenger, Michael K, Moiseev, Sergey I

Volltext

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial von Hillmen, Peter, Eichhorst, Barbara, Brown, Jennifer R, Lamanna, Nicole, O'Brien, Susan M, Tam, Constantine S, Qiu, Lugui, Kazmierczak, Maciej, Zhou, Keshu, Šimkovič, Martin, Mayer, Jiří, Gillespie-Twardy, Amanda, Shadman, Mazyar, Ferrajoli, Alessandra, Ganly, Peter S, Weinkove, Robert, Grosicki, Sebastian, Mital, Andrzej, Robak, Tadeusz, Österborg, Anders, Yimer, Habte A, Salmi, Tommi, Ji, Meng, Yecies, Jessica, Idoine, Adam, Wu, Kenneth, Huang, Jane, Jurczak, Wojciech

Volltext

Zanubrutinib monotherapy for patients with treatment-naive chronic lymphocytic leukemia and 17p deletion von Tam, Constantine S., Robak, Tadeusz, Ghia, Paolo, Kahl, Brad S., Walker, Patricia, Janowski, Wojciech, Simpson, David, Shadman, Mazyar, Ganly, Peter S., Laurenti, Luca, Opat, Stephen, Tani, Monica, Ciepluch, Hanna, Verner, Emma, Simkovi, Martin, Osterborg, Anders, Trneny, Marek, Tedeschi, Alessandra, Paik, Jason C., Kuwahara, Sowmya B., Feng, Shibao, Ramakrishnan, Vanitha, Cohen, Aileen, Huang, Jane, Hillmen, Peter, Brown, Jennifer R.

Volltext

Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment von Brown, JR, Eichhorst, B, Hillmen, P, Jurczak, W, Kazmierczak, M, Lamanna, N, O'Brien, SM, Tam, CS, Qiu, LG, Zhou, KS, Simkovic, M, Mayer, J, Gillespie-Twardy, A, Ferrajoli, A, Ganly, PS, Weinkove, R, Grosicki, S, Mital, A, Robak, T, Osterborg, A, Yimer, HA, Salmi, T, Wang, MDY, Fu, LN, Li, J, Wu, KN, Cohen, A, Shadman, M

Volltext

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia von Brown, Jennifer R., Eichhorst, Barbara, Hillmen, Peter, Jurczak, Wojciech, Kaźmierczak, Maciej, Lamanna, Nicole, O’Brien, Susan M., Tam, Constantine S., Qiu, Lugui, Zhou, Keshu, Simkovic, Martin, Mayer, Jiri, Gillespie-Twardy, Amanda, Ferrajoli, Alessandra, Ganly, Peter S., Weinkove, Robert, Grosicki, Sebastian, Mital, Andrzej, Robak, Tadeusz, Osterborg, Anders, Yimer, Habte A., Salmi, Tommi, Wang, Megan-Der-Yu, Fu, Lina, Li, Jessica, Wu, Kenneth, Cohen, Aileen, Shadman, Mazyar

Volltext

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia von Burger, Jan A, Tedeschi, Alessandra, Barr, Paul M, Robak, Tadeusz, Owen, Carolyn, Ghia, Paolo, Bairey, Osnat, Hillmen, Peter, Bartlett, Nancy L, Li, Jianyong, Simpson, David, Grosicki, Sebastian, Devereux, Stephen, McCarthy, Helen, Coutre, Steven, Quach, Hang, Gaidano, Gianluca, Maslyak, Zvenyslava, Stevens, Don A, Janssens, Ann, Offner, Fritz, Mayer, Jiří, O’Dwyer, Michael, Hellmann, Andrzej, Schuh, Anna, Siddiqi, Tanya, Polliack, Aaron, Tam, Constantine S, Suri, Deepali, Cheng, Mei, Clow, Fong, Styles, Lori, James, Danelle F, Kipps, Thomas J

Volltext

Written advice can provide a safe and acceptable alternative to new patient assessment for selected referrals to haematologists von Ganly, Peter S, Keeman, Helen, Spearing, Ruth L, Smith, Mark P, Patton, Nigel, Merriman, Eileen G, Gibbons, Steve S

Volltext

BRUIN CLL-313: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic... von Jurczak, Wojciech, Dartigeas, Caroline, Coscia, Marta, Ganly, Peter S., Al-Jazayrly, Ghassan, Wang, Chunxiao, Bao, Katherine, Leow, Ching Ching, Shahda, Safi, Zinzani, Pier Luigi

Volltext

Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study von Flowers, Christopher, Zinzani, Pier Luigi, Mayer, Jiří, Bijou, Fontanet, de Oliveira, Ana C., Song, Yuqin, Zhang, Qingyuan, Merli, Michele, Bouabdallah, Krimo, Ganly, Peter S., Zhang, Huilai, Yuen, Sam, Kingsley, Ed, Assouline, Sarit E., Auer, Rebecca, Kim, Pil, Greenbaum, Adam, Huang, Sha, Delarue, Richard, Trotman, Judith

Volltext

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Ch... von Brown, Jennifer R., Eichhorst, Barbara F., Lamanna, Nicole, O'Brien, Susan M., Tam, Constantine S., Qiu, Luqui, Kaźmierczak, Maciej, Jurczak, Wojciech, Zhou, Keshu, Simkovic, Martin, Mayer, Jiri, Gillespie-Twardy, Amanda L., Ferrajoli, Alessandra, Ganly, Peter S., Weinkove, Robert, Grosicki, Sebastian, Mital, Andrzej, Robak, Tadeusz, Osterborg, Anders, Yimer, Habte A., Wang, Megan (Der Yu), Salmi, Tommi, Wang, Liping, Li, Jessica, Wu, Kenneth, Cohen, Aileen Cleary, Shadman, Mazyar

Volltext

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial von Mateos, Maria-Victoria, Schjesvold, Fredrik, Simpson, David, George, Anupkumar, Goldschmidt, Hartmut, Larocca, Alessandra, Chanan-Khan, Asher, Sherbenou, Daniel, Avivi, Irit, Benyamini, Noam, Matsumoto, Morio, Suzuki, Kenshi, Ribrag, Vincent, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, Kher, Uma, Farooqui, Mohammed, Marinello, Patricia, Lonial, Sagar, Grigoriadis, George, Catalano, John, LeBlanc, Richard, Elemary, Mohamed, Bahlis, Nizar, Facon, Thierry, Karlin, Lionel, Ribrag, Vincent, Attal, Michel, Goldschmidt, Hartmut, Engelhardt, Monika, Weisel, Katja, Mackensen, Andreas, Nagler, Arnon, Ben Yehuda, Dina, Avivi, Irit, Benyamini, Noam, Magen-Nativ, Hila, Palumbo, Antonio, Cavo, Michele, Tobinai, Kensei, Suzuki, Kenshi, Kosugi, Hiroshi, Taniwaki, Masafumi, Sunami, Kazutaka, Matsumoto, Morio, Ando, Kiyoshi, Ganly, Peter, Blacklock, Hilary, Simpson, David, George, Anupkumar, Schjesvold, Fredrik, Lahuerta, Juan, Oriol Rocafiguera, Albert, Mateos, Maria, Rodriguez-Otero, Paula, Larson, Sarah, Atanackovic, Djordje, Devarakonda, Srinivas, Morganstein, Neil, Saylors, Gene, Oliff, Ira, Kirkel, Dean, Shtivelband, Mikhail, Yuen, Carrie, Yee, Andrew, Htut, Myo, Raza, Shahzad, Chhabra, Saurabh, Hari, Parameswaran, Bank, Bruce, Malek, Ehsan, Gasparetto, Cristina, Faroun, Ycaoub, Sherbenou, Daniel, Kreisle, William, Singhal, Seema, Rosenblatt, Jacalyn, Usmani, Saad, Lee, Wes, Safah, Hana, Lutzky, Jose, Pan, Dorothy, Baron, Ari, Manges, Robert, Steis, Ronald, Moreb, Jan, Callander, Natalie, Anz, Bertrand, Raptis, Anastasios, Stampleman, Laura, Melear, Jason, Boyd, Thomas, Garbo, Lawrence, Klein, Leonard, Shao, Spencer, Lyons, Roger, McIntyre, Kristi, Yasenchak, Christopher, Yimer, Habte

Volltext

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic L... von Brown, Jennifer R., Eichhorst, Barbara, Hillmen, Peter, Lamanna, Nicole, O'Brien, Susan M., Tam, Constantine S., Qiu, Lugui, Kaźmierczak, Maciej, Jurczak, Wojciech, Zhou, Keshu, Šimkovič, Martin, Mayer, Jiri, Gillespie-Twardy, Amanda L., Ferrajoli, Alessandra, Ganly, Peter S., Weinkove, Robert, Grosicki, Sebastian, Mital, Andrzej, Robak, Tadeusz, Österborg, Anders, Yimer, Habte A., Salmi, Tommi, Wang, Megan (Der Yu), Fu, Lina, Li, Jessica, Wu, Kenneth, Cohen, Aileen, Shadman, Mazyar

Volltext

Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the phase... von Zinzani, Pier Luigi, Mayer, Jiří, Auer, Rebecca, Bijou, Fontanet, de Oliveira, Ana C., Flowers, Christopher, Merli, Michele, Bouabdallah, Krimo, Ganly, Peter S., Johnson, Roderick, Yuen, Sam, Kingsley, Ed, Tumyan, Gayane, Assouline, Sarit E., Ivanova, Elena, Kim, Pil, Huang, Jane, Delarue, Richard, Trotman, Judith

Volltext

Fibrinogen Hillsborough: a novel γGly309Asp dysfibrinogen with impaired clotting von Mullin, Jennifer L., Brennan, Stephen O., Ganly, Peter S., George, Peter M.

Volltext

Poster: CLL-129 BRUIN CLL-313: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Sm... von Levy, Alex, Jurczak, Wojciech, Dartigeas, Caroline, Coscia, Marta, Ganly, Peter S., Al-Jazayrly, Ghassan, Wang, Chunxiao, Bao, Katherine, Leow, Ching Ching, Shahda, Safi, Zinzani, Pier Luigi

Volltext

CLL-129 BRUIN CLL-313: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymp... von Levy, Alex, Jurczak, Wojciech, Dartigeas, Caroline, Coscia, Marta, Ganly, Peter S., Al-Jazayrly, Ghassan, Wang, Chunxiao, Bao, Katherine, Leow, Ching Ching, Zinzani, Pier Luigi

Volltext

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma von Hungria, Vania, Robak, Pawel, Hus, Marek, Zherebtsova, Vera, Ward, Christopher, Ho, P. Joy, Ribas de Almeida, Ana Carolina, Hajek, Roman, Kim, Kihyun, Grosicki, Sebastian, Sia, Hanlon, Bryant, Adam, Pitombeira de Lacerda, Marcelo, Aparecida Martinez, Gracia, Sureda Balarí, Anna Maria, Sandhu, Irwindeep, Cerchione, Claudio, Ganly, Peter, Dimopoulos, Meletios, Fu, Chengcheng, Garg, Mamta, Abdallah, Al-Ola, Oriol, Albert, Gatt, Moshe E., Cavo, Michele, Rifkin, Robert, Fujisaki, Tomoaki, Mielnik, Michał, Pirooz, Nick, McKeown, Astrid, McNamara, Simon, Zhou, Xiangdong, Nichols, Maureen, Lewis, Eric, Rogers, Rachel, Baig, Hena, Eccersley, Lydia, Roy-Ghanta, Sumita, Opalinska, Joanna, Mateos, María-Victoria

Volltext

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results fr... von Brown, Jennifer R., Robak, Tadeusz, Ghia, Paolo, Kahl, Brad S., Walker, Patricia, Janowski, Wojciech, Chan, Henry, Shadman, Mazyar, Ganly, Peter S., Laurenti, Luca, Opat, Stephen, Tani, Monica, Ciepluch, Hanna, Verner, Emma, Šimkovič, Martin, Österborg, Anders, Trněný, Marek, Tedeschi, Alessandra, Blombery, Piers, Paik, Jason C., Yin, Fangfang, Feng, Shibao, Ramakrishnan, Vanitha, Huang, Jane, Hillmen, Peter, Tam, Constantine S.

Volltext

CLL-115 First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Le... von Brown, Jennifer R., Hillmen, Peter, Eichhorst, Barbara, Lamanna, Nicole, O'Brien, Susan, Tam, Constantine S., Qiu, Lugui, Kazmierczak, Maciej, Zhou, Keshu, Šimkovič, Martin, Mayer, Jiri, Gillespie-Twardy, Amanda, Shadman, Mazyar, Ferrajoli, Alessandra, Ganly, Peter S., Weinkove, Robert, Salmi, Tommi, Wu, Kenneth, Novotny, William, Jurczak, Wojciech

Volltext

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm... von Tam, Constantine S., Robak, Tadeusz, Ghia, Paolo, Kahl, Brad S., Walker, Patricia, Janowski, Wojciech, Simpson, David, Shadman, Mazyar, Ganly, Peter S., Laurenti, Luca, Opat, Stephen, Tani, Monica, Ciepluch, Hanna, Verner, Emma, Simkovic, Martin, Österborg, Anders, Trněný, Marek, Tedeschi, Alessandra, Paik, Jason, Marimpietri, Carol, Feng, Shibao, Huang, Jane, Hillmen, Peter, Brown, Jennifer R.

Volltext